Publications by authors named "Jason Harb"

Claim this Profile
C
CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia.
Anjali Advani, Olatoyosi Odenike, Deepa Jeyakumar, Raya Mawad, Olga Frankfurt, Jason G Harb

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response.
Naveen Pemmaraju, Tim C P Somervaille, Francesca Palandri, Claire Harrison, Rami S Komrokji, Jason Harb

Blood Neoplasia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-X /BCL-2 inhibition with navitoclax.
Naveen Pemmaraju, Jacqueline S Garcia, Andrew Perkins, Jason G Harb, Andrew J Souers

Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Amer M Zeidan, Uma Borate, Daniel A Pollyea, Andrew M Brunner, Fernando Roncolato, Jason G Harb

Am J Hematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Naveen Pemmaraju, Jacqueline S Garcia, Jalaja Potluri, Jason G Harb, Yan Sun

Lancet Haematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Claire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, James M Foran, Srdan Verstovsek, Jason Harb

J Clin Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on Antiproliferative and PP2A-Activating Functions.
Giovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, Justin J Ellis, Jason G Harb

Blood Cancer Discov· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Paolo Neviani, Jason G Harb

Blood· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Paolo Neviani, Jason G Harb, Joshua J Oaks, Ramasamy Santhanam, Christopher J Walker

J Clin Invest· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Joshua J Oaks, Ramasamy Santhanam, Christopher J Walker, Steve Roof, Jason G Harb

Blood· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Houda Alachkar, Ramasamy Santhanam, Jason G Harb, David M Lucas, Joshua J Oaks

J Hematol Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.
Danilo Perrotti, Jason G Harb

Leuk Lymphoma· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.
Anna M Eiring, Jason G Harb, Paolo Neviani, Christopher Garton, Joshua J Oaks

Cell· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice.
Stefan Costinean, Sukhinder K Sandhu, Irene M Pedersen, Esmerina Tili, Rossana Trotta, Jason Harb

Blood· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis.
Jason G Harb, Brenda I Chyla, Claudia S Huettner

Blood· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstration of a method for the direct determination of polycyclic aromatic hydrocarbons in submerged sediments.
Timothy J Grundl, Joseph H Aldstadt, Jason G Harb, Randy W St Germain, Robert C Schweitzer

Environ Sci Technol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis